Fund moves

Dexcom (DXCM): Bellevue Group AG added to its stake +34K shares

Bellevue Group AG added to its stake in Dexcom, per its Q2 2026 13F.

822K
Shares reported · +34K vs prior quarter
1.2%
Disclosed portfolio weight
$55.4M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$425K)
  2. Jul 6, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  3. Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
  4. Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
  5. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  6. Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
  7. Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market
  8. Aug 11, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  9. Aug 12, 2026InsiderDirector sold ~$89K of DXCM shares in the open market
  10. Aug 14, 2026InsiderOfficer sold ~$156K of DXCM shares in the open market

What came next

  1. Aug 20, 2026Insider · 1 personInsiders: 3 sales (~$2.4M)
  2. Aug 27, 2026InsiderOfficer sold ~$227K of DXCM shares in the open market
  3. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.”
  4. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.”
  5. Sep 10, 2026InsiderOfficer sold ~$303K of DXCM shares in the open market
  6. Sep 14, 2026InsiderDirector sold ~$130K of DXCM shares in the open market
  7. Sep 15, 2026Insider · 2 peopleInsiders: 2 sales (~$692K)
  8. Sep 28, 2026InsiderOfficer sold ~$221K of DXCM shares in the open market
  9. Oct 15, 2026InsiderOfficer sold ~$145K of DXCM shares in the open market
  10. Oct 27, 2026InsiderOfficer sold ~$202K of DXCM shares in the open market
  11. Oct 29, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  12. Nov 10, 20265% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.0%
  13. Nov 16, 2026InsiderOfficer sold ~$142K of DXCM shares in the open market
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

How this filing works

Explore the data

Common questions

What does this filing report about Dexcom (DXCM) stock?

Bellevue Group AG added to its stake in Dexcom, per its Q2 2026 13F. Now 822K shares, $55.4M reported value, 1.2% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 14, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dexcom recently?

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.

Does this mean DXCM stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data